Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression

Škereňová, Markéta; Mikulová, Veronika; Čapoun, Otakar; Zima, Tomáš; Tesařová, Petra

doi:10.5507/bp.2017.022

Cited by 22 publications

(15 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, the patients with PCa demonstrated a significantly higher concentration of serum VEGF (179.3 versus 123.3 pg/mL, resp.). The results obtained by Skerenova et al had shown higher levels to have occurred in men with castration resistant prostate cancer (CRPC) than in healthy men (332 versus 239 pg/mL); however, the median concentration in PCa group was much higher than in our results (332 versus 179.3 pg/mL) [ 67 ]. It may result from the assortment of patients, as Skerenova et al examined patients with highly advanced cancer.…”

Section: Discussioncontrasting

confidence: 83%

Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer

Fryczkowski¹,

Bułdak

Hejmo

et al. 2018

Disease Markers

View full text Add to dashboard Cite

Background Prostate cancer (PCa) is the first in terms of occurrence in Europe and second in Poland. The PCa risk factors include: genetic load, obesity, diet rich in fat, hypertriglyceridemia, and exposure to androgens. The prostate-specific antigen (PSA) level may be elevated in prostate cancer or other prostate disorders. Fat tissue secretes adipocytokines, which increase the risk of cancer development and metastasis. Objectives The aims of the study were to investigate the relationship between circulating levels of PSA, adipocytokines: omentin, leptin, hepatocyte growth factor (HGF), and vascular endothelial growth factor (VEGF) in serum obtained from patients with benign prostate hyperplasia (BPH) and prostate cancer (PCa). Methods Forty patients diagnosed with BPH and forty diagnosed with PCa were assessed for the purpose of the study. The concentrations of omentin, leptin, HGF, and VEGF were determined using enzyme-linked immunosorbent assays (EIA). Results PSA level was significantly higher in the PCa group than in BPH (18.2 versus 9 ng/mL, p < 0.01), while volume of prostate gland was significantly higher in the BPH group than in PCa (39.1 versus 31.1 cm3, p = 0.02). HGF, VEGF, omentin, and leptin concentrations were significantly higher in PCa group than in BPH (359.5 versus 294.9 pg/mL, p = 0.04; 179.3 versus 127.3 pg/mL, p < 0.01; 478.8 versus 408.3 ng/mL, p = 0.01; 15.7 versus 11.2 ng/mL, p = 0.02, resp.). The multiple logistic regression analysis demonstrated that only omentin and PSA levels were independent predictors of PCa in studied subjects. Conclusions PSA level as well as the level of omentin may be valuable markers of PCa with clinical significance, when compared to PSA.

show abstract

Section: Discussioncontrasting

confidence: 83%

Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer

Fryczkowski¹,

Bułdak

Hejmo

et al. 2018

Disease Markers

View full text Add to dashboard Cite

show abstract

“…Multivariate analysis indicated that serum MMP‐9 and HER2 ECD levels could accurately discriminate patients with brain metastasis from controls (Darlix et al, ). MMP‐2 serum levels have also been reported to be significantly higher in HER2‐positive breast cancer patients who developed central nervous system metastasis (Skerenova et al, ). High baseline serum MMP‐2 levels correlated with better DFS and OS in breast cancer patients treated with bevacizumab‐based neoadjuvant chemotherapy (BEVERLY‐2 study), while low baseline MMP‐9 associated with better OS and DFS (Tabouret et al, ).…”

Section: Diagnosis and Prognosis Of Cancers By Mmpsmentioning

confidence: 99%

Metalloproteinases and their roles in human cancer

Roy

Morad

Jedinak

et al. 2019

The Anatomical Record

View full text Add to dashboard Cite

It is now widely appreciated that members of the matrix metalloproteinase (MMP) family of enzymes play a key role in cancer development and progression along with many of the hallmarks associated with them. The activity of these enzymes has been directly implicated in extracellular matrix remodeling, the processing of growth factors and receptors, the modulation of cell migration, proliferation, and invasion, the epithelial to mesenchymal transition, the regulation of immune responses, and the control of angiogenesis. Certain MMP family members have been validated as biomarkers of a variety of human cancers including those of the breast, brain, pancreas, prostate, ovary, and others. The related metalloproteinases, the A disintegrin and metalloproteinases (ADAMs), share a number of these functions as well. Here, we explore these essential metalloproteinases and some of their disease-associated activities in detail as well as some of their complementary translational potential. Anat Rec, 303:1557-1572, 2020.Matrix metalloproteinases (MMPs) are a multigene family of metal-dependent endopeptidases that play important and diverse roles in normal physiological and pathological processes. The classic domain structure of MMP family members can be found in Figure 1 (Roy et al., 2009). MMPs include an amino-terminal signal peptide required for secretion, a pro-domain that mediates latency via a cysteine-switch mechanism and a Zn 2+ -dependent catalytic domain that is responsible for enzymatic function. A majority of MMPs also contain a C-terminal hemopexinlike domain that provides substrate specificity. MMP activity is the rate-limiting step in extracellular matrix (ECM) degradation and it can regulate the activity of other proteases, growth factors, cytokines, and cell-surface ligands

show abstract

“…In the past decade, many potential biomarkers have been discovered including circulating proteins, 36 mutated DNAs, RNAs, 37 , 38 and serum proteins. Serum markers are the simplest to measure for routine clinical assessments and epidemiological studies.…”

Section: Discussionmentioning

confidence: 99%

Matrix metalloproteinase-7 may serve as a novel biomarker for cervical cancer

Zhu

Zheng

et al. 2018

OTT

View full text Add to dashboard Cite

BackgroundThe biological and clinical significance of matrix metalloproteinase-7 (MMP-7) in cervical cancer remains unknown. Here, we investigated the function of MMP-7 in cervical cancer cells and evaluated its clinical significance in both tissues and serum from cervical cancer patients.MethodsFirst, we analyzed the expression of MMP-7 in cervical cancer using Oncomine microarray data and examined its expression in cervical tissues by quantitative real-time polymerase chain reaction and Western blotting. Second, we utilized gene silencing to explore the role of MMP-7 in cells. Finally, we examined the MMP-7 levels in patients with cervical cancer and normal serum by enzyme-linked immunosorbent assay. Moreover, we further investigated the relationship between MMP-7 expression and pathological features.ResultsThe mRNA and protein MMP-7 levels were higher in cervical cancer tissues than in healthy controls. Silencing of MMP-7 significantly decreased cervical cancer cell proliferation, migration, and invasion. The serum MMP-7 levels were significantly higher in cervical cancer patients than in healthy subjects (P<0.01). Further, higher MMP-7 expression was associated with increased lymph metastasis (P=0.021), pathological grade (P=0.039, P=0.047), and clinical stage (P=0.049, P=0.046).ConclusionMMP-7 appears to act as an oncogene in cervical cancer cells and is involved in cell proliferation, migration, and invasion. MMP-7 expression was significantly higher in the tissue and serum of cervical cancer patients compared to healthy individuals and was correlated with increased pathalogical grade, clinical stage, and lymph metastasis. Therefore, our data provide novel evidence that MMP-7 may be a clinically relevant biomarker for cervical cancer.

show abstract

Circulating tumor cells and serum levels of MMP-2, MMP-9 and VEGF as markers of the metastatic process in patients with high risk of metastatic progression

Cited by 22 publications

References 44 publications

Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer

Circulating Levels of Omentin, Leptin, VEGF, and HGF and Their Clinical Relevance with PSA Marker in Prostate Cancer

Metalloproteinases and their roles in human cancer

Matrix metalloproteinase-7 may serve as a novel biomarker for cervical cancer

Contact Info

Product

Resources

About